GBT new logo.png
Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
February 27, 2017 16:05 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization...
GBT new logo.png
Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions
February 16, 2017 16:05 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced initiation of the Phase 1 Basecamp (GBT440-011) clinical trial,...
GBT new logo.png
Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters
February 14, 2017 08:30 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that a paper describing the discovery of GBT440 and its ability...
GBT new logo.png
Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease
January 18, 2017 08:30 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen...
GBT new logo.png
Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 03, 2017 16:05 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 35th Annual J.P. Morgan Healthcare...
GBT new logo.png
Global Blood Therapeutics Added to NASDAQ Biotechnology Index
December 16, 2016 08:30 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has been selected for addition to the NASDAQ Biotechnology...
GBT new logo.png
Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program
November 30, 2016 16:05 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will host an investor webcast on Monday, December 5,...
GBT new logo.png
Global Blood Therapeutics Announces Pivotal Study for GBT440 in Sickle Cell Disease with Primary Hemoglobin Endpoint
October 24, 2016 16:05 ET | Global Blood Therapeutics
HOPE – A Phase 3 Clinical Trial to Initiate in December Company to Host Conference Call and Webcast Today at 1:30 p.m. PT/ 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE)...
GBT new logo.png
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
October 12, 2016 08:00 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment...
GBT new logo.png
Global Blood Therapeutics Joins Sickle Cell Disease (SCD) Coalition in Support of SCD Community with Goal to Improve Treatment and Care
September 06, 2016 09:05 ET | Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment...